Reduced cytocidal efficacy for adriamycin in cultured human carcinoma cells depleted of polyamines by difluoromethylornithine treatment
- PMID: 3080235
Reduced cytocidal efficacy for adriamycin in cultured human carcinoma cells depleted of polyamines by difluoromethylornithine treatment
Abstract
We have studied the effect of pretreatment with difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, on the cytocidal responses of four human adenocarcinoma cell lines to Adriamycin (ADR). The cell lines utilized included HuTu-80 (duodenum), HT-29 (colon), ME-180 (cervix), and A-427 (lung). A 48-h DFMO pretreatment reduced putrescine and spermidine content to less than 10 and less than 1% of control levels and decreased spermine to between 70 and 30% of controls. Plating efficiency assays were used to generate ADR dose-response survival curves for DFMO-treated and control cultures. The DFMO pretreatment significantly protected human adenocarcinoma cells from the lethal effects of ADR. Addition of exogenous putrescine to the DFMO-treated cultures 24 h before treatment with ADR restored their cytocidal response to ADR to near control levels. Putrescine had no effect on cell survival in cultures that were not pretreated with DFMO. These observations suggest that DFMO-induced protection from ADR may be a specific consequence of DFMO-induced inhibition of polyamine biosynthesis. Alternatively, since ADR efficacy varies directly with cellular growth rates and DFMO inhibits proliferation, the protection may have resulted from DFMO-induced growth inhibition. Comparison of ADR uptake in DFMO-pretreated and control cells showed that the protection did not result from decreased intracellular accumulation of ADR.
Similar articles
-
Chemosensitization of cultured human carcinoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by difluoromethylornithine-induced polyamine depletion.Cancer Res. 1985 May;45(5):2132-8. Cancer Res. 1985. PMID: 3921237
-
Altered cell cycle phase distributions in cultured human carcinoma cells partially depleted of polyamines by treatment with difluoromethylornithine.Cancer Res. 1986 Jan;46(1):47-53. Cancer Res. 1986. PMID: 3079590
-
Effects of DFMO-induced polyamine depletion on human tumor cell sensitivity to antineoplastic DNA-crosslinking drugs.Cancer Chemother Pharmacol. 1986;17(1):16-20. doi: 10.1007/BF00299860. Cancer Chemother Pharmacol. 1986. PMID: 3084110
-
Comparisons between sensitive and resistant human tumor cell lines regarding effects of polyamine depletion on chloroethylnitrosourea efficacy.Cancer Res. 1990 Feb 1;50(3):521-6. Cancer Res. 1990. PMID: 2137022
-
Polyamine Inhibition with DFMO: Shifting the Paradigm in Neuroblastoma Therapy.J Clin Med. 2025 Feb 7;14(4):1068. doi: 10.3390/jcm14041068. J Clin Med. 2025. PMID: 40004600 Free PMC article. Review.
Cited by
-
Treatment with inhibitors of polyamine biosynthesis, which selectively lower intracellular spermine, does not affect the activity of alkylating agents but antagonizes the cytotoxicity of DNA topoisomerase II inhibitors.Br J Cancer. 1997;75(7):1028-34. doi: 10.1038/bjc.1997.176. Br J Cancer. 1997. PMID: 9083339 Free PMC article.
-
Schedule dependent potentiation of antitumor drug effects by alpha-difluoromethylornithine in human gastric carcinoma cells in vitro.Invest New Drugs. 1990;8 Suppl 1:S9-18. doi: 10.1007/BF00171979. Invest New Drugs. 1990. PMID: 1696247
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials